Japan's health ministry has started considering ways to promote the use of follow-on products of very expensive original biological drugs. Options include increasing out-of-pocket costs of patients wh ...
Inhibrx said the encouraging results in treating the rare, slow growing cancer that often begins in the bone, bolster its plans to file a BLA in the second quarter of 2026. The company’s stock (NASDAQ ...
Adocia SA is looking to further apply its Biochaperone formulation technology to metabolic disorders, Olivier Soula, Adocia ...
California has launched a program to manufacture and sell lower-cost insulin to people with diabetes. State officials say ...
Gov. Gavin Newsom announced Thursday he is rolling out an effort to lower the price of insulin to $11. CalRx, the state-run ...
SACRAMENTO, California — California will start selling low-cost insulin in January, becoming the first state in the nation to ...
Non inferior HbA1c reduction at 26 weeks (primary endpoint) Significant reduction of the rise of blood glucose after a test meal (key secondary endpoint) Blood glucose level, monitored by 10-point ...
LYON, France, October 15, 2025--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and ...
Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences, Poznan, Poland Background: Euglycemic diabetic ketoacidosis (euDKA) is a rare but potentially life-threatening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback